- Active not recruitingPHASE3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is looking at a medicine called semaglutide for a liver condition called non-alcoholic steatohepatitis (NASH). Participants will receive either semaglutide or a dummy medicine. It's a long study, lasting about 5 years, with regular clinic visits.
For: Non-alcoholic SteatohepatitisUnited States · Argentina · Australia - Recruiting
Weight Loss in Adults Using Semaglutide (Real-world Study)
This study looks at how a medicine called semaglutide helps adults lose weight in real-life settings. Doctors decide who receives the treatment. It aims to see how effective semaglutide is for people who are overweight or obese, following their usual healthcare.
For: Overweight · ObesityUnited States · United Kingdom - Active not recruitingPHASE3
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study is looking at a new medicine called CagriSema to help people with obesity lose weight. It compares CagriSema to a dummy medicine over three years. Participants won't know if they're getting the active medicine or the dummy medicine. The aim is to see how well it works long-term.
For: ObesityUnited States · Belgium · Canada - Active not recruitingPHASE3
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
This study looks at how a medicine called semaglutide helps children and teenagers lose weight. Participants get weekly injections of either semaglutide or a dummy medicine. All also receive healthy lifestyle advice. The study lasts about 2.5 years.
For: ObesityUnited States · Austria · Belgium - RecruitingPHASE3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.
For: Overweight · ObesityUnited States · Australia · Austria - Active not recruitingPHASE3
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study looks at how a new medicine called CagriSema helps people who are overweight lose weight. It compares CagriSema to other medicines and a dummy medicine. Participants will take a weekly injection, and the study will last about 3 and a half years.
For: ObesityUnited States · Argentina · Australia - Active not recruitingPHASE4
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
This study looks at how a weekly injection, semaglutide, helps teenagers aged 12-15 with obesity to lose weight and keep it off. All participants will receive the treatment for at least three years, aiming to understand its effectiveness for weight management.
For: ObesityUnited States · Belgium · Canada - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis
This study is looking at a new medicine called efinopegdutide for adults with a liver condition called non-alcoholic steatohepatitis (NASH). It compares this new medicine with another one called semaglutide or a dummy treatment to see if it improves the liver and is safe.
Spain · Belgium · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities
This study is comparing two medicines, Tirzepatide and Semaglutide, to see which is more effective and safer for helping adults with obesity or overweight, who also have other health issues, to lose weight. It's looking at how much weight people lose and other health changes.
For: Obesity OverweightGermany · Belgium · Poland - AuthorisedTherapeutic confirmatory (Phase III)
The effect of semaglutide therapy on hepatic fat content and on the acute reponse of liver fat to high-fat load in obese MASLD patients
This study looks at how a medicine called semaglutide affects fat in the liver of men with obesity and a condition called MASLD. We want to see if it reduces liver fat and how the liver responds to fatty foods after taking the medicine.
For: ObesityCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
This study is testing a new combination medicine, CagriSema, for people with type 2 diabetes. It's looking at whether this combined medicine is better at controlling blood sugar and helping with weight loss than existing treatments, including its individual components, semaglutide and cagrilintide.
For: Type 2 diabetesDenmark · Sweden · Slovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
For: Chronic Kidney Disease · Type 2 diabetesSpain · Hungary · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
This study is testing different new medicines, alone or in combination, to see if they can help improve liver damage and reduce alcohol use in people with liver problems caused by alcohol. One of the medicines is similar to a type already used for diabetes.
For: alcohol-related liver diseaseGermany · Greece · Bulgaria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Defining the Glucagon Unit: Investigating the Impact on Energy Expenditure and Glucose Level Deviation in healthy volunteers
This study for healthy men aged 18 and over investigates how different substances, including medicines for weight loss and hormones, affect the body's energy use and blood sugar levels. Researchers want to understand these effects to help treat conditions like obesity.
For: ObesityLatvia - Ongoing, recruitingTherapeutic use (Phase IV)
Young adults with early-onset obesity treated with semaglutide -The RESETTLE study - a randomized double blind placebo-controlled clinical trial
This study, called RESETTLE, is looking at how a medicine called semaglutide helps young adults with obesity. It compares semaglutide to a dummy medicine to see if it makes a difference to their weight and overall health.
For: ObesityDenmark - Enrolling by invitation
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
This study looks at how a medicine called Wegovy (semaglutide) is used in real life to help people with obesity. It will follow participants for two years to see how it affects weight, body size, and quality of life.
For: ObesitySpain · Switzerland · United Kingdom - Active not recruitingPHASE3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study, called REDEFINE 3, investigates a new medicine, CagriSema, for people with heart and blood vessel diseases. It aims to see if CagriSema can reduce the risk of serious events like heart attacks and strokes.
For: Cardiovascular DiseaseUnited States · Argentina · Australia - Not yet recruitingPHASE4
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
This study looks at how new weight loss drugs, semaglutide and tirzepatide, affect blood vessels and blood pressure. Researchers want to understand if these drugs have direct benefits on the heart and blood system, beyond just helping people lose weight.
For: Cardiovascular DiseasesUnited Kingdom - Active not recruitingPHASE3
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
This study investigates how a medicine called semaglutide affects eye problems in people with type 2 diabetes over five years. Participants will get either semaglutide or a dummy medicine, injected once a week, along with their usual diabetes treatments.
For: Diabetes Mellitus, Type 2United States · Brazil · Bulgaria - AuthorisedTherapeutic exploratory (Phase II)
Weight management with orismilast alone or in combination with s.c. semaglutide (WELOSITI)
This study looks at a new medicine called orismilast, sometimes with semaglutide, to help adults aged 18 and over manage their weight. Researchers want to see how much weight people lose over 16 weeks.
For: obesityDenmark - AuthorisedTherapeutic use (Phase IV)
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.
This study looks at how a diabetes medicine, semaglutide, affects inflammation and blood vessel health in people with Type 2 diabetes. We want to see if adding semaglutide to regular treatment helps reduce harmful effects in the body compared to standard treatment alone.
For: Type 2 diabetes mellitusItaly